255 related articles for article (PubMed ID: 29767848)
21. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
22. Quantitative assessment of the JAK2 V617F allele burden: equivalent levels in peripheral blood and bone marrow.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Leukemia; 2008 Jan; 22(1):194-5. PubMed ID: 17625603
[No Abstract] [Full Text] [Related]
23. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
24. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients.
Barbui T; Thiele J; Carobbio A; Guglielmelli P; Rambaldi A; Vannucchi AM; Tefferi A
Am J Hematol; 2014 Jun; 89(6):588-90. PubMed ID: 24535932
[TBL] [Abstract][Full Text] [Related]
25. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis.
Barbui T; Thiele J; Carobbio A; Vannucchi AM; Tefferi A
Leukemia; 2015 Apr; 29(4):992-3. PubMed ID: 25425199
[No Abstract] [Full Text] [Related]
26. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
[TBL] [Abstract][Full Text] [Related]
27. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Alvarez-Larrán A; Senín A; Fernández-Rodríguez C; Pereira A; Arellano-Rodrigo E; Gómez M; Ferrer-Marin F; Martínez-López J; Camacho L; Colomer D; Angona A; Navarro B; Cervantes F; Besses C; Bellosillo B; Hernández-Boluda JC
Br J Haematol; 2017 Sep; 178(5):764-771. PubMed ID: 28542718
[TBL] [Abstract][Full Text] [Related]
28. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
29. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.
Ianotto JC; Curto-Garcia N; Lauermanova M; Radia D; Kiladjian JJ; Harrison CN
Haematologica; 2019 Aug; 104(8):1580-1588. PubMed ID: 30679326
[TBL] [Abstract][Full Text] [Related]
30. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
[TBL] [Abstract][Full Text] [Related]
31. Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
Hsu HC
J Chin Med Assoc; 2007 Mar; 70(3):89-93. PubMed ID: 17389152
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.
Zalcberg IR; Ayres-Silva J; de Azevedo AM; Solza C; Daumas A; Bonamino M
Haematologica; 2011 Mar; 96(3):e18-20. PubMed ID: 21357711
[No Abstract] [Full Text] [Related]
33. Myeloproliferative neoplasms.
Publicover A; Medd P
Clin Med (Lond); 2013 Apr; 13(2):188-92. PubMed ID: 23681871
[TBL] [Abstract][Full Text] [Related]
34. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
Marty C; Lacout C; Martin A; Hasan S; Jacquot S; Birling MC; Vainchenker W; Villeval JL
Blood; 2010 Aug; 116(5):783-7. PubMed ID: 20472827
[TBL] [Abstract][Full Text] [Related]
35. A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.
Bellosillo B; Martínez-Avilés L; Gimeno E; Florensa L; Longarón R; Navarro G; Salar A; Espinet B; Solé F; Serrano S; Besses C
Leukemia; 2007 Jun; 21(6):1331-2. PubMed ID: 17361221
[No Abstract] [Full Text] [Related]
36. JAK2 V617F polycythemia vera and essential thrombocythemia: dynamic clinical features associated with long-term outcomes.
Sureau L; Buors C; Ianotto JC; Boyer F; Tanguy-Schmidt A; Roy L; Cayssials E; Cailly L; Chomel JC; Chauveau A; Orvain C; Mansier O; Ranta D; Robles M; Gyan E; Hérault O; Nimubona S; Marchand T; Lippert E; Riou J; Ugo V; Luque Paz D
Blood Cancer J; 2022 Apr; 12(4):56. PubMed ID: 35395836
[No Abstract] [Full Text] [Related]
37. Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders.
Langabeer SE; Ni Ainle F; Conneally E; Lawler M
Ir J Med Sci; 2007; 176(2):105-9. PubMed ID: 17440677
[TBL] [Abstract][Full Text] [Related]
38. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
39. JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.
Guglielmelli P; Barosi G; Pieri L; Antonioli E; Bosi A; Vannucchi AM
Haematologica; 2009 Jan; 94(1):144-6. PubMed ID: 19042918
[No Abstract] [Full Text] [Related]
40. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
